-+ 0.00%
-+ 0.00%
-+ 0.00%

Passage Bio Reports Updated Data From Ongoing Phase 1/2 upliFT-D Clinical Trial Evaluating PBFT02 For Treatment Of Frontotemporal Dementia With Granulin Mutations

Benzinga·04/20/2026 11:08:06
Listen to the news

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels 

FDA feedback from recent Type C meeting indicated a randomized controlled registrational trial will be required for PBFT02 in FTD-GRN

The Company initiated a strategic review process intended to maximize shareholder value

PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations. In addition, the Company shared feedback from a recent Type C meeting with the United States Food and Drug Administration (FDA) on the likely registrational pathway for PBFT02 in FTD-GRN. The Company has also announced it has engaged Wedbush PacGrow as a financial advisor and has initiated a review of strategic alternatives to maximize shareholder value.